US 12,280,068 B1
Uses of a co-crystal of psilocybin and psilocin
Peter Silverstone, Calgary (CA); Robert Laprairie, Saskatoon (CA); and Deborah Kurrasch, Calgary (CA)
Assigned to Zylorion Health Inc., Calgary (CA)
Filed by ZYLORION HEALTH INC., Calgary (CA)
Filed on Nov. 8, 2024, as Appl. No. 18/941,779.
Claims priority of provisional application 63/597,415, filed on Nov. 9, 2023.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/675 (2006.01); A61K 31/4045 (2006.01); A61P 25/00 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 31/4045 (2013.01); A61P 25/00 (2018.01)] 18 Claims
 
1. A method of increasing the number of neuronal progenitor cells in a subject in need thereof, comprising administering to the subject a crystalline form of psilocin and psilocybin:

OG Complex Work Unit Chemistry
wherein the crystalline form is co-crystal Form A; and
wherein Form A is characterized by a XRPD pattern comprising a significant peak at a 2θ angle of 10.1° and about 19.16°.